Literature DB >> 1410567

Dosimetry of intracavitary placements for uterine and cervical carcinoma: results of orthogonal film, TLD, and CT-assisted techniques.

K S Kapp1, G F Stuecklschweiger, D S Kapp, A G Hackl.   

Abstract

A total of 720 192Ir high-dose-rate (HDR) applications in 331 patients with gynecological tumors were analyzed to evaluate the dose to normal tissues from brachytherapy. Based on the calculations of bladder base, bladder neck, and rectal doses derived from orthogonal films the planned tumor dose or fractionation was altered in 20.4% of intracavitary placements (ICP) for cervix carcinoma and 9.2% of ICP for treatment of the vaginal vault. In 13.8% of intracervical and 8.1% of intravaginal treatments calculated doses to both the bladder and rectum were greater than or equal to 140% of the initially planned dose fraction. Doses at the bladder base were significantly higher than at the bladder neck (p less than 0.001). In 17.5% of ICP the dose to the bladder base was at least twice as high as to the bladder neck. The ratio of bladder base dose to the bladder neck was 1.5 (+/- 1.19 SD) for intracervical and 1.46 (+/- 1.14 SD) for intravaginal applications. The comparison of calculated doses from orthogonal films with in-vivo readings showed a good correlation of rectal doses with a correlation coefficient factor of 0.9556. CT-assisted dosimetry, however, revealed that the maximum doses to bladder and rectum were generally higher than those obtained from films with ratios of 1-1.7 (average: 1.44) for the bladder neck, 1-5.4 (average: 2.42) for the bladder base, and 1.1-2.7 (average: 1.37) for the rectum. When doses to the specified reference points of bladder neck and rectum from orthogonal film dosimetry were compared with the corresponding points on CT scans, similar values were obtained for both methods with a maximum deviation of +/- 10%. Despite the determination of multiple reference points our study revealed that this information was inadequate to predict doses to the entire rectum and bladder. If conventional methods are used for dosimetry it is recommended that doses to the bladder base should be routinely calculated, since single point measurements at the bladder neck seriously underestimate the dose to the bladder. Also the rectal dose should be determined at several points over the length of the implant due to the wide range of anatomic variations possible.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1410567     DOI: 10.1016/0167-8140(92)90372-2

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  13 in total

Review 1.  Imaging-guided brachytherapy for locally advanced cervical cancer: the main process and common techniques.

Authors:  Zhongshan Liu; Yangzhi Zhao; Yunfeng Li; Jing Sun; Xia Lin; Tiejun Wang; Jie Guo
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

2.  Sigmoid dose using 3D imaging in cervical-cancer brachytherapy.

Authors:  Caroline L Holloway; Marie-Lynn Racine; Robert A Cormack; Desmond A O'Farrell; Akila N Viswanathan
Journal:  Radiother Oncol       Date:  2009-08-06       Impact factor: 6.280

Review 3.  Image-based brachytherapy for cervical cancer.

Authors:  John A Vargo; Sushil Beriwal
Journal:  World J Clin Oncol       Date:  2014-12-10

4.  Design and development of an inflatable latex balloon to reduce rectal and bladder doses for patients undergoing high dose rate brachytherapy.

Authors:  P Raghukumar; Raghu Ram K Nair; Abi S Aprem; Saju Bhasi; Suja Sisupal; V Padmanbhan
Journal:  J Med Phys       Date:  2009-01

5.  A retrospective analysis of rectal and bladder dose for gynecological brachytherapy treatments with GZP6 HDR afterloading system.

Authors:  Mohammad Taghi Bahreyni Toossi; Mahdi Ghorbani; Yasha Makhdoumi; Mojtaba Taheri; Fatemeh Homaee Shandiz; Siavash Zahed Anaraki; Ali Soleimani Meigooni
Journal:  Rep Pract Oncol Radiother       Date:  2012-07-15

6.  Bladder (ICRU) dose point does not predict urinary acute toxicity in adjuvant isolated vaginal vault high-dose-rate brachytherapy for intermediate-risk endometrial cancer.

Authors:  Lucas Gomes Sapienza; Antonio Aiza; Maria José Leite Gomes; Michael Jenwei Chen; Antonio Cassio de Assis Pellizzon; David B Mansur; Glauco Baiocchi
Journal:  J Contemp Brachytherapy       Date:  2015-10-13

7.  Dosimetric evaluation of rectum and bladder using image-based CT planning and orthogonal radiographs with ICRU 38 recommendations in intracavitary brachytherapy.

Authors:  Swamidas V Jamema; Sherly Saju; Umesh Mahantshetty; S Pallad; D D Deshpande; S K Shrivastava; K A Dinshaw
Journal:  J Med Phys       Date:  2008-01

8.  Comparison of conventional and CT-based planning for intracavitary brachytherapy for cervical cancer: target volume coverage and organs at risk doses.

Authors:  Cem Onal; Gungor Arslan; Erkan Topkan; Berrin Pehlivan; Melek Yavuz; Ezgi Oymak; Aydin Yavuz
Journal:  J Exp Clin Cancer Res       Date:  2009-07-01

Review 9.  Dose Summation Strategies for External Beam Radiation Therapy and Brachytherapy in Gynecologic Malignancy: A Review from the NRG Oncology and NCTN Medical Physics Subcommittees.

Authors:  Hayeon Kim; Yongsook C Lee; Stanley H Benedict; Brandon Dyer; Michael Price; Yi Rong; Ananth Ravi; Eric Leung; Sushil Beriwal; Mark E Bernard; Jyoti Mayadev; Jessica R L Leif; Ying Xiao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-06-17       Impact factor: 7.038

10.  Dosimetry and toxicity outcomes in postoperative high-dose-rate intracavitary brachytherapy for endometrial carcinoma.

Authors:  Eric D Donnelly; Sunpreet Rakhra; Irene Helenowski; Mahesh Gopalkrishnan; John Lurain; Julian Schink; Diljeet Singh; Jonathan Strauss; William Small
Journal:  J Contemp Brachytherapy       Date:  2012-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.